Actively Recruiting
Evaluating Safety and Antitumor Activity of BG-75098 Alone and with BGB-43395 and Fulvestrant in Adults with Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-09-28
105
Participants Needed
23
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, how the body processes and reacts to the drug BG-75098, and its preliminary ability to fight tumors in adults with advanced solid tumors. The study includes two phases Phase 1a dose escalation and Phase 1b dose expansion. It aims to understand BG-75098 alone and combined with BGB-43395 and fulvestrant in treating these cancers. Participants will receive BG-75098 orally either alone or combined with BGB-43395 also oral and fulvestrant given by intramuscular injection. The study first tests increasing doses of BG-75098 alone and with the other drugs to find the recommended dose. Then, participants receive the recommended doses either as monotherapy or combination therapy, depending on the group. During the study, participants are monitored for side effects, drug levels in the blood, and tumor response. Assessments include tracking adverse events up to 30 days after the last dose and up to 2 years, measuring how long the response lasts, time to response, and disease progression. Blood samples are taken at specific times between treatment cycles to analyze drug concentration and behavior. Overall participation can last up to two years with regular evaluations.
CONDITIONS
Brief Title
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here